A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

August 31, 2009

Conditions
Respiratory Distress Syndrome, AdultAcute Lung InjuryAcute Respiratory Distress Syndrome
Interventions
DRUG

Fish oil (eicosapentaenoic acid and docosahexanoic acid)

Liquid fish oil 7.5cc enterally every 6 hours

Trial Locations (5)

83706

St. Alphonsus Medical Center, Boise

97239

Oregon Health Sciences University, Portland

98104

Harborview Medical Center, Seattle

05401

University of Vermont/Fletcher Allen Health Care, Burlington

M5B1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

American Thoracic Society

OTHER

collaborator

Acute Respiratory Distress Syndrome Foundation

OTHER

collaborator

American Society for Parenteral and Enteral Nutrition

OTHER

lead

University of Washington

OTHER

NCT00351533 - A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) | Biotech Hunter | Biotech Hunter